Viracta Therapeutics, Inc.
R&D Day - October 4, 2023
Introduction:
Mark Rothera
President and Chief Executive Officer
Forward-Looking Statements
This communication contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on current expectations, estimates and projections based on information currently available to management of Viracta Therapeutics, Inc. ("Viracta" or the "Company"), including, without limitation, statements regarding: Viracta's development pipeline; the details, timeline and expected progress for Viracta's ongoing trials; the expected ability of Viracta to undertake certain activities and accomplish certain goals with respect to its clinical program in EBV+ lymphoma, EBV+ solid tumors, other virus-associated malignancies or its programs; expectations regarding future therapeutic and commercial potential with respect to Viracta's clinical program in EBV+ lymphoma, EBV+ solid tumors or other virus-associated malignancies; the ability of Viracta to support multiple new drug application filings and approvals from the NAVAL-1 trial; Viracta's plans to meet with the FDA to discuss preliminary results from the NAVAL-1 trial, amending the NAVAL-1 protocol to add patients as necessary to enable registration and provide other program updates; Viracta's cash projections and the sufficiency of its cash and cash equivalents to fund operations into late 2024; the future availability of capital under Viracta's credit facility; the expected future milestones and key upcoming events and their significance; and other statements that are not historical facts. Risks and uncertainties related to Viracta that may cause actual results to differ materially from those expressed or implied in any forward-looking statement include, but are not limited to: Viracta's ability to successfully enroll patients in and complete its ongoing and planned clinical trials; Viracta's plans to develop and commercialize its product candidates, including all oral combinations of nanatinostat and valganciclovir; the timing of initiation of Viracta's planned clinical trials; the timing of the availability of data from Viracta's clinical trials; the possibility that previous preclinical and clinical results may not be predictive of future clinical results; the timing of any planned investigational new drug application or new drug application; Viracta's plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of Viracta's product candidates; Viracta's ability to identify additional products or product candidates with significant commercial potential; developments and projections relating to Viracta's competitors and its industry; the impact of government laws and regulations; Viracta's ability to protect its intellectual property position; and Viracta's estimates regarding future expenses, capital requirements and need for additional financing.
These risks and uncertainties may be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption "Risk Factors" and elsewhere in Viracta's most recent filings with the SEC and any subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at www.sec.gov. The forward-looking statements included in this communication are made only as of the date hereof. Viracta assumes no obligation and does not intend to update these forward-looking statements, except as required by law or applicable regulation.
3
Epstein-Barr Virus (EBV): A High Global Cancer Priority
EBV+ malignancies account for ~2% of all new cancer cases globally
EBV positivity, by lymphoma subtype1, 2,3
Peripheral T-cell lymphoma* (PTCL) | 40-65% |
Diffuse large B-cell lymphoma (DLBCL) | 5-15% |
Post-transplant lymphoproliferative | 60-80% |
disorders (PTLD) | |
EBV positivity, by solid tumor subtype4
Nasopharyngeal carcinoma (NPC) | 75-95% |
Gastric cancer (GC) | 8-10% |
~90% of the adult population are | Latency confers resistance to anti- | >300,000 new cases/year of | Responsible for |
infected with EBV | viral therapies and facilitates | EBV+ lymphomas and solid | ~180,000 cancer deaths/year5 |
evasion of immune detection | tumors5 |
The incidence of EBV-associated cancers is likely greater, impacting more cancer types
1Haverkos BM, et al. Int J Cancer. 2017; 140:1899-1906; Dupuis J et al. Blood. 2006;108:4163-9;2Swerdlow SH et al. (2017) WHO classification of Tumours of the Haematopoietic and Lymphoid Tissues; | 4 |
3EBV positivity varies by geography; 4Wong Y, et al. Journal of Cancer Research and Clinical Oncology (2022) 148:31-46 Exp. Therapeutic Med. 15: 3687, 2018; 5Kahn,G, et al. BMJ 10:1136, 2020. |
*Includes Peripheral T-cell lymphoma, NOS and Angioimmunoblastic T-cell lymphoma
Viracta is Developing a Precision Medicine to Treat Unique Subsets of EBV+ Lymphoma with Adverse Survival Outcomes
Currently limited or no targeted therapy options for EBV-associated cancers
Peripheral T-cell Lymphoma1 | Diffuse Large B-cell Lymphoma2 |
(Overall Survival) | (Progression-Free Survival) |
Addressing patient
populations with high unmet medical need
PTCL EBV+ Rate: 40-65% | DLBCL EBV+ Rate: 5-15% |
1Haverkos BM, et al. Int J Cancer. 2017; 140:1899-1906; Dupuis J et al. Blood. 2006;108:4163-9,2Lu TX et al. Sci Rep. 2015;5:1-14 | 5 |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Viracta Therapeutics Inc. published this content on 04 October 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 October 2023 13:49:02 UTC.